These findings indicate that clinicians can now recognise semaglutide as a vascular protective medication, with benefits that extend beyond lowering weight or A1C, said Subodh Verma (University of Toronto, Toronto, Canada), senior author of the STRIDE trial
Naunyn-Schmiedeberg S Archives of Pharmacology, 399 (1), 815832
The standard protocol begins with 0.25 mg once weekly for four weeks, increasing to 0.5 mg, with further increases to 1 mg or 2 mg only if needed and tolerated
Semaglutide is contraindicated in patients with a personal or family history of certain types of thyroid cancer, specifically thyroid C-cell tumors such as medullary thyroid carcinoma (MTC), or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2)
In turn, the body required less pancreatic insulin to flush out excess glucose because the rate at which glucose was entering the blood decreased